CN103463047B - The application of Lycojaponicumin B in preparation treatment cancer of biliary duct medicine - Google Patents
The application of Lycojaponicumin B in preparation treatment cancer of biliary duct medicine Download PDFInfo
- Publication number
- CN103463047B CN103463047B CN201310436764.0A CN201310436764A CN103463047B CN 103463047 B CN103463047 B CN 103463047B CN 201310436764 A CN201310436764 A CN 201310436764A CN 103463047 B CN103463047 B CN 103463047B
- Authority
- CN
- China
- Prior art keywords
- lycojaponicumin
- medicine
- bile duct
- cancer
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses the application of Lycojaponicumin B in preparation treatment human bile duct cancer medicine, belong to technical field of new application of medicine.The present invention is found by external MTT antineoplastic activity evaluation, and the growth of Lycojaponicumin B to human bile duct carcinoma strain RBE also has significant inhibitory action.Therefore, Lycojaponicumin B for the preparation of anti-cancer of biliary duct medicine, can have good development prospect.Belong to first public for the purposes of the Lycojaponicumin B that the present invention relates in preparation treatment human bile duct cancer medicine, because framework types belongs to brand-new framework types, and its inhibit activities for human bile duct carcinoma is unexpectedly strong.
Description
Technical field
The present invention relates to the novelty teabag of compound L ycojaponicumin B, particularly relate to the application of Lycojaponicumin B in the anti-cancer of biliary duct medicine of preparation.
Technical background
Cancer is to one of maximum disease of human life's health hazard, has a large amount of people to die from cancer every year.The research and development of cancer therapy drug are the focuses of study of pharmacy always.74% is had to be natural product or derivatives thereof in antitumor drug, if paclitaxel and derivant thereof are exactly the current reasonable antitumor drug of effect clinically.Therefore, from natural product, anticancer compound is found or lead compound has great importance.
The compound L ycojaponicumin B that the present invention relates to is one and delivers (Wang in 2012, X.J.etal., 2012.Lycojaponicumins A-C, Three Alkaloids with an UnprecedentedSkeleton from Lycopodium japonicum.Organic Letters 14 (10), New skeleton compound 2614-2617.), this compound has brand-new framework types, the purposes in preparation treatment cancer of biliary duct medicine that the present invention relates to is belonged to first public, because framework types belongs to brand-new framework types, and its inhibit activities for cholangiocarcinoma cell is unexpectedly strong, there is not the possibility being provided any enlightenment by other compounds, possesses outstanding substantive distinguishing features, control simultaneously for cancer of biliary duct obviously has significant progress.
Summary of the invention
The invention provides compound L ycojaponicumin B and prepare the application in antitumor drug.
The present invention adopts following technical scheme: the application of Lycojaponicumin B in the anti-cancer of biliary duct medicine of preparation, and the structural formula of Lycojaponicumin B is as shown in formula I:
The present invention is found by external MTT antineoplastic activity evaluation, and the growth of Lycojaponicumin B to human bile duct carcinoma strain RBE also has significant inhibitory action, suppresses the IC of this 1 strain Growth of Cells
50value is 1.61 ± 0.13 μMs.Therefore, Lycojaponicumin B for the preparation of anti-cancer of biliary duct medicine, can have good development prospect.
The purposes of the Lycojaponicumin B that the present invention relates in preparation treatment cancer of biliary duct medicine belongs to first public, because framework types belongs to brand-new framework types, and its inhibit activities for cholangiocarcinoma cell is unexpectedly strong, there is not the possibility being provided any enlightenment by other compounds, possess outstanding substantive distinguishing features, the control simultaneously for cancer of biliary duct obviously has significant progress.
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not by any restriction of specific embodiment, but be limited by claim.
Detailed description of the invention
The preparation method of compound L ycojaponicumin B involved in the present invention is see document (Wang, X.J.et al., 2012.Lycojaponicumins A-C, Three Alkaloids with an Unprecedented Skeleton from Lycopodiumjaponicum.Organic Letters 14 (10), 2614-2617.).
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not by any restriction of specific embodiment, but be limited by claim.
Embodiment 1: the preparation of compound L ycojaponicumin B tablet involved in the present invention:
Get 20 g of compound Lycojaponicumin B, add the customary adjuvant 180 grams preparing tablet, mixing, conventional tablet presses makes 1000.
Embodiment 2: the preparation of compound L ycojaponicumin B capsule involved in the present invention:
Get 20 g of compound Lycojaponicumin B, add prepare capsule customary adjuvant as starch 180 grams, mixing, encapsulatedly makes 1000.
Its pharmaceutically active is further illustrated below by pharmacodynamic experiment.
Experimental example: adopt mtt assay assessing compound Lycojaponicumin B to the growth inhibited effect of human bile duct carcinoma strain
1. method: the cell being in growth logarithmic (log) phase: human bile duct carcinoma strain RBE (buying from Chinese Academy of Sciences's cell bank) is with 1.5 × 10
4concentration kind is in 96 orifice plates.Original culture medium is sucked after cell culture 24h is adherent.Test is divided into blank group, drug treating group.Blank group changes 1640 culture medium containing 10% hyclone; It is 100 μMs that drug treating group is changed containing concentration, 50 μMs, 10 μMs, 1 μM, 0.1 μM, the culture medium of the Lycojaponicumin B of 0.01 μM and 0.001 μM.After cultivating 48h, add the MTT of concentration 5mg/mL, continue to be put in CO
2incubator cultivates 4h, then 100 μ L supernatants are sucked along culture fluid top, add 100 μ L DMSO, 10min is placed in dark place, microplate reader (Sunrise Products) is utilized to measure light absorption value (wavelength 570nm), and calculating cell survival according to light absorption value, 6 repeating holes are established in each process.Cell survival rate (%)=Δ OD
drug treating/ Δ OD
blank× 100.
2. result: the growth of Lycojaponicumin B to human bile duct carcinoma strain RBE has significant inhibitory action.This compound suppresses the IC of human bile duct carcinoma strain RBE growth
50value is: 1.61 ± 0.13 μMs.
Shown by above-described embodiment, the growth of Lycojaponicumin B of the present invention to human bile duct carcinoma strain RBE has good inhibitory action.Prove thus, it is active that Lycojaponicumin B of the present invention has anti-cancer of biliary duct, can for the preparation of anti-cancer of biliary duct medicine.
Claims (1)
1. the application of Lycojaponicumin B in preparation treatment cancer of biliary duct medicine, described compound L ycojaponicumin B structure as
formula Ishown in:
formula I.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310436764.0A CN103463047B (en) | 2013-09-23 | 2013-09-23 | The application of Lycojaponicumin B in preparation treatment cancer of biliary duct medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310436764.0A CN103463047B (en) | 2013-09-23 | 2013-09-23 | The application of Lycojaponicumin B in preparation treatment cancer of biliary duct medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103463047A CN103463047A (en) | 2013-12-25 |
| CN103463047B true CN103463047B (en) | 2015-09-16 |
Family
ID=49788245
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310436764.0A Active CN103463047B (en) | 2013-09-23 | 2013-09-23 | The application of Lycojaponicumin B in preparation treatment cancer of biliary duct medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103463047B (en) |
-
2013
- 2013-09-23 CN CN201310436764.0A patent/CN103463047B/en active Active
Non-Patent Citations (1)
| Title |
|---|
| Lycojaponicumins A-C,Three Alkaloids with an Unprecedented Skeleton from Lycopodium japonicum;Xiao-Jing Wang, et al;《Organic Letters》;20120508;第14卷(第10期);2614-2617 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103463047A (en) | 2013-12-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103463046B (en) | The application of Lycojaponicumin A in preparation treatment colorectal cancer medicine | |
| CN102872086B (en) | The application of Houttuynoid A in treatment skin carcinoma medicine | |
| CN103463047B (en) | The application of Lycojaponicumin B in preparation treatment cancer of biliary duct medicine | |
| CN103463058B (en) | The application of Lycojaponicumin A in treatment cancer of biliary duct medicine | |
| CN103446144B (en) | The application of Lycojaponicumin C in preparation treatment cancer of biliary duct medicine | |
| CN103463045B (en) | The application of Lycojaponicumin A in preparation treatment blindgut cancer | |
| CN103463056B (en) | The application of Lycojaponicumin A in preparation treatment tongue cancer drug | |
| CN103446141B (en) | The application of Lycojaponicumin C in preparation treatment tongue cancer drug | |
| CN103462964B (en) | The application of Incarviatone A in preparation treatment cancer of biliary duct medicine | |
| CN103446130B (en) | Lycojaponicumin B is preparing the application in Hepatoma therapy medicine | |
| CN103446122B (en) | The application of Lycojaponicumin B in preparation treatment carcinoma of prostate medicine | |
| CN103463059B (en) | The application of Lycojaponicumin B in preparation treatment laryngeal carcinoma medicine | |
| CN103463051B (en) | The application of Lycojaponicumin A in preparation treatment medicine for nasopharyngeal | |
| CN103463060B (en) | The application of Lycojaponicumin C in preparation treatment endometrial cancer drug | |
| CN103463049B (en) | The application of Lycojaponicumin B in preparation treatment breast cancer medicines | |
| CN103463033B (en) | The application of Lycojaponicumin B in preparation treatment gastric cancer medicament | |
| CN103463022B (en) | Application of Lycojaponicumin B in medicine for treating ileocecum cancer | |
| CN103463070B (en) | The application of Lycojaponicumin C in preparation treatment breast cancer medicines | |
| CN103463042B (en) | Application of Lycojaponicumin A in drugs for treating prostatic cancer | |
| CN103405416B (en) | The application of Chukrasone B in preparation treatment endometrial cancer drug | |
| CN103405420B (en) | The application of Chukrasone B in preparation treatment medicine for nasopharyngeal | |
| CN103405447B (en) | The application of Chukrasone A in preparation treatment medicine for nasopharyngeal | |
| CN103463027B (en) | The application of Lycojaponicumin A in treatment laryngeal carcinoma medicine | |
| CN103463069B (en) | The application of Lycojaponicumin C in preparation treatment medicine for nasopharyngeal | |
| CN103340871B (en) | The application of Myriberine A in preparation treatment cancer of biliary duct medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP02 | Change in the address of a patent holder | ||
| CP02 | Change in the address of a patent holder |
Address after: 221300 east side of Yimeng Mountain Road, Pizhou Economic Development Zone, Pizhou City, Pizhou City, Xuzhou, Jiangsu Patentee after: Nanjing Guangkangxie Biomedical Technology Co., Ltd. Address before: Metro Technology Building No. 69 Olympic Avenue in Jianye District of Nanjing city in Jiangsu province 210019 01 5 storey buildings Patentee before: Nanjing Guangkangxie Biomedical Technology Co., Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20180427 Address after: 200120 room 304, 3 lane, 720 lane, Cai Lun Road, China (Shanghai) free trade zone. Patentee after: Kai Hui Sagi Biotechnology (Shanghai) Co., Ltd. Address before: 221300 east of Xuzhou Yimeng Mountain Road, Pizhou Economic Development Zone, Pizhou, Xuzhou, Jiangsu Patentee before: Nanjing Guangkangxie Biomedical Technology Co., Ltd. |